T Lymphocyte Activation Antigen CD86 - Pipeline Review, H1 2018

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H1 2018

Summary

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Cluster of Differentiation 86 or CD86 or B7-2 is a protein expressed on antigen-presenting cells. It plays a critical role in the early events of T-cell activation and co stimulation of naive T-cells, such as deciding between immunity and energy.

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively.

Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Dermatology, Genito Urinary System And Sex Hormones, Oncology, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Alopecia, Autoimmune Disorders, Dermatomyositis, Diffuse Large B-Cell Lymphoma, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener Polyangiitis), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Transplant Rejection, Uveitis and Vitiligo.

The latest report T Lymphocyte Activation Antigen CD86 - Pipeline Review, H1 2018, outlays comprehensive information on the T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86)
- The report reviews T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope


List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Overview 6
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 11
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Therapeutics Assessment 13
Assessment by Mechanism of Action 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Companies Involved in Therapeutics Development 17
3SBio Inc 17
Bristol-Myers Squibb Co 17
KAHR medical Ltd 18
Momenta Pharmaceuticals Inc 19
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Drug Profiles 20
abatacept - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
abatacept biosimilar - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
abatacept biosimilar - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
abatacept biosimilar - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
abatacept biosimilar - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
KAHR-102 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Dormant Products 37
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Discontinued Products 38
T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Product Development Milestones 39
Featured News & Press Releases 39
Feb 23, 2018: Orencia for Intravenous Infusion 250 mg, Selective T-cell Co-stimulation Modulator: Approval for Additional Indication of Active Polyarticular Juvenile Idiopathic Arthritis for Partial Change in Approved items of Manufacturing and Marketing Approval in Japan 39
Dec 09, 2017: Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant 39
Nov 13, 2017: Bristol-Myers Squibbs Orencia Rejects for Use within NHS Scotland 40
Nov 02, 2017: Bristol-Myers Squibb to Showcase Companys Progress in Researching Personalized Medicine for the Potential Treatment of Autoimmune Diseases at 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 41
Nov 01, 2017: Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept) 46
Jul 26, 2017: Bristol-Myers Squibbs ORENCIA (abatacept) Receives Second European Commission Approval in Less than a Year - New Approval for Treatment of Active Psoriatic Arthritis 47
Jul 06, 2017: Bristol-Myers Squibbs ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults 48
Jun 14, 2017: Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017) 49
Jun 08, 2017: Bristol-Myers Squibb Announces Availability of New ORENCIA (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis 53
Mar 30, 2017: Supplemental Application of Orencia (Abatacept) Intravenous Injection 250 mg a Selective T-cell Co-stimulation Modulator for Treatment of Juvenile Idiopathic Arthritis for a Partial Change in Approved Items of Manufacturing and Marketing Approval 55
Mar 13, 2017: Bristol-Myers Squibbs Orencia Rejects For Use Within NHS Scotland 55
Nov 14, 2016: Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 56
Nov 10, 2016: Bristol-Myers Squibb to Showcase New Data Spanning Rheumatoid Arthritis and Other Autoimmune Diseases at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting 57
Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept) 61
Sep 06, 2016: European Commission Approves Bristol-Myers Squibbs ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018 7
Number of Products under Development by Therapy Areas, H1 2018 8
Number of Products under Development by Indication, H1 2018 9
Number of Products under Development by Companies, H1 2018 11
Products under Development by Companies, H1 2018 12
Number of Products by Stage and Mechanism of Actions, H1 2018 13
Number of Products by Stage and Route of Administration, H1 2018 15
Number of Products by Stage and Molecule Type, H1 2018 16
Pipeline by 3SBio Inc, H1 2018 17
Pipeline by Bristol-Myers Squibb Co, H1 2018 18
Pipeline by KAHR medical Ltd, H1 2018 18
Pipeline by Momenta Pharmaceuticals Inc, H1 2018 19
Dormant Projects, H1 2018 37
Discontinued Products, H1 2018 38

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018 7
Number of Products under Development by Therapy Areas, H1 2018 8
Number of Products under Development by Top 10 Indications, H1 2018 9
Number of Products by Stage and Mechanism of Actions, H1 2018 13
Number of Products by Routes of Administration, H1 2018 14
Number of Products by Stage and Routes of Administration, H1 2018 14
Number of Products by Stage and Molecule Type, H1 2018 16

2018 Leading Animal Health Companies: Marketing Tactics, Technological Know-How and Global Sales Segment Forecasts

This new report provides global animal health market outlook and leading suppliers' strategies, marketing tactics, and technological know-how. The report presents a worldwide strategic overview of the animal health market,

USD 3450 View Report

2018 Leading Animal Health Companies: Business Strategies, Marketing Tactics and Global Sales Segment Forecasts

This new report provides global animal health market outlook and leading suppliers' strategies, marketing tactics, and technological know-how. The report presents a worldwide strategic overview of the animal health market,

USD 3450 View Report

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2018

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2018Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4

USD 3500 View Report

Global Lymphocyte Activation Gene 3 Protein Market Research Report 2018

Lymphocyte Activation Gene 3 Protein Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions,

USD 2850 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available